Incidental detection in the DANCAVAS trial was limited by design and did not bias the cost effectiveness conclusion

Editorial

Rikke Søgaard et al. Eur Heart J. 2023.

. 2023 Jan 1;44(1):70.

doi: 10.1093/eurheartj/ehac646.

No abstract available

Conflict of interest statement

Conflict of interest: none declared.

Cost effectiveness of population screening vs. no screening for cardiovascular disease: the Danish Cardiovascular Screening trial (DANCAVAS).
Søgaard R, Diederichsen ACP, Rasmussen LM, Lambrechtsen J, Steffensen FH, Frost L, Egstrup K, Urbonaviciene G, Busk M, Lindholt JS. Søgaard R, et al. Eur Heart J. 2022 Nov 1;43(41):4392-4402. doi: 10.1093/eurheartj/ehac488. Eur Heart J. 2022. PMID: 36029019 Clinical Trial.
More costs than benefits from screening for cardiovascular disease with computed tomography in the DANCAVAS study.
Andersen NH, Jørgensen T, Brodersen JB. Andersen NH, et al. Eur Heart J. 2023 Jan 1;44(1):68-69. doi: 10.1093/eurheartj/ehac634. Eur Heart J. 2023. PMID: 36370002 No abstract available.